Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL16871771 | 0.98 | PDPK1 (0.35) | PDPK1PARP1KDM4EALDH1A1HPGD | |
| SCHEMBL1193368 | 0.79 | PDPK1 (0.34) | PDPK1PARP1 | |
| SCHEMBL2938699 | 0.79 | PDPK1 (0.37) | PDPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4451632 | 0.79 | XDH (0.40) | PDPK1PARP1KDM4ECSNK2A1DYRK1A | |
| SCHEMBL9925954 | 0.79 | PDPK1 (0.34) | PDPK1PARP1DYRK1A | |
| SCHEMBL9465638 | 0.79 | PDPK1 (0.34) | PDPK1PARP1CSNK2A2CSNK2A1MEN1 | |
| SCHEMBL753115 | 0.79 | PDK2 (0.38) | PDPK1PARP1KDM4EALDH1A1HPGD | |
| SCHEMBL21684954 | 0.79 | CSNK2A1 (0.36) | PDPK1PARP1CSNK2A2CSNK2A1 | |
| SCHEMBL1371017 | 0.79 | PDPK1 (0.31) | PDPK1PARP1 | |
| SCHEMBL11334542 | 0.79 | LMNA (0.33) | PDPK1PARP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119433594-A | Lignin derived carbon-alloy-metal oxide heterojunction catalyst and preparation method thereof | 广西大学 | 2025-02-14 | — | — | CN | claimed |
| CN-117199398-A | Molybdenum-doped nickel-cobalt-copper lattice stretching alloy catalyst and preparation method thereof | 广西大学 | 2023-12-08 | — | — | CN | claimed |
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-119433594-A | Lignin derived carbon-alloy-metal oxide heterojunction catalyst and preparation method thereof | 广西大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORP (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024192323-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-117199398-A | Molybdenum-doped nickel-cobalt-copper lattice stretching alloy catalyst and preparation method thereof | 广西大学 | 2023-12-08 | — | — | CN | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7307167-B2 | Production method of 2,6-dihalopurine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-12-11 | — | — | US | disclosed |
| CN-1553909-A | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | — | 2004-12-08 | — | — | CN | disclosed |
| EP-1368342-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002050062-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | HSP90B1, HSPBP1, HSP90AB2P | PDPK1 2216/4885PARP1 653/4885KDM4E 3806/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | PDPK1 87/4885PARP1 351/4885KDM4E 1381/4885 |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | KHK, KHDRBS1, KHSRP | PDPK1 155/4885PARP1 4253/4885KDM4E 641/4885 |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | PDE12, TBXA2R, PDE6G | PDPK1 2635/4885PARP1 2601/4885KDM4E 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.